{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T17:24:46Z","timestamp":1789061086680,"version":"build-2803163510"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,7,18]],"date-time":"2022-07-18T00:00:00Z","timestamp":1658102400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,7,18]],"date-time":"2022-07-18T00:00:00Z","timestamp":1658102400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Periostin is an extracellular matrix protein that has been known to be implicated in fibrillogenesis and cell migration, including cancer metastasis. Periostin overexpression in cancer cells and\/or intervening stroma is usually related to tumor progression and poor patient outcomes in various human cancers; however, its role in urothelial carcinoma, especially upper urinary tract urothelial carcinomas (UTUCs), remains inconclusive.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Samples from 126 consecutive cases of invasive UTUC (69 renal pelvic cancers and 57 ureteral cancers) were histologically reviewed and analyzed for periostin expression using immunohistochemistry. The intensities of immunoreactivity and the fraction of positive cancer cells and stroma (i.e., epithelial and stromal expression, respectively) were classified into four categories each (intensity, 0\u20133; fraction, 0\u201325%\u2009=\u20091; 26\u201350%\u2009=\u20092; 51\u201375%\u2009=\u20093; and\u2009&gt;\u200975%\u2009=\u20094). The overall score was determined by multiplying both scores, and overall scores\u2009\u2265\u20096 were considered to indicate high periostin expression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Among 126 UTUCs, 55 (44%; 27 renal pelvic and 28 ureteral cancers) showed high stromal periostin expression. None of the cases were considered to have high epithelial periostin expression. High stromal periostin expression was associated with non-papillary gross findings, higher pathological T category, lymphovascular invasion, concomitant carcinoma in situ, subtype histology, lymph node metastasis, positive surgical margins, high tumor budding, and high tumor-associated immune cell status. Multivariate analysis revealed that high stromal periostin expression was an independent predictor of overall survival (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.00072, hazard ratio\u2009=\u20093.62), and lymphovascular invasion and high stromal periostin expression were independent predictors of cancer-specific survival (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.032 and 0.020, hazard ratio\u2009=\u20092.61 and 3.07, respectively).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Stromal periostin expression was often observed in invasive UTUCs with adverse clinicopathological factors and may be a useful predictor of patient outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12885-022-09893-7","type":"journal-article","created":{"date-parts":[[2022,7,18]],"date-time":"2022-07-18T05:02:49Z","timestamp":1658120569000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Prognostic impact of stromal periostin expression in upper urinary tract urothelial carcinoma"],"prefix":"10.1186","volume":"22","author":[{"given":"Kosuke","family":"Miyai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuki","family":"Kawamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiichi","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susumu","family":"Matsukuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitoshi","family":"Tsuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,7,18]]},"reference":[{"key":"9893_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21654","volume":"71","author":"RL Siegel","year":"2021","unstructured":"Siegel RL, Miller KD, Fuchs H, Jemal A. Cancer statistics, 2021. CA Cancer J Clin. 2021;71:7\u201333.","journal-title":"CA Cancer J Clin"},{"key":"9893_CR2","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.eururo.2020.05.042","volume":"79","author":"M Roupr\u00eat","year":"2021","unstructured":"Roupr\u00eat M, Babjuk M, Burger M, Capoun O, Cohen D, Comp\u00e9rat EM, et al. European association of urology guidelines on upper urinary tract urothelial carcinoma: 2020 update. Eur Urol. 2021;79:62\u201379.","journal-title":"Eur Urol"},{"key":"9893_CR3","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.eururo.2012.02.030","volume":"62","author":"G Lughezzani","year":"2012","unstructured":"Lughezzani G, Burger M, Margulis V, Matin SF, Novara G, Roupret M, et al. Prognostic factors in upper urinary tract urothelial carcinomas: a comprehensive review of the current literature. Eur Urol. 2012;62:100\u201314.","journal-title":"Eur Urol"},{"key":"9893_CR4","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.urology.2016.07.036","volume":"100","author":"F Petrelli","year":"2017","unstructured":"Petrelli F, Yasser Hussein MI, Vavassori I, Barni S. Prognostic factors of overall survival in upper urinary tract carcinoma: a systematic review and meta-analysis. Urology. 2017;100:9\u201315.","journal-title":"Urology"},{"key":"9893_CR5","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1111\/j.1464-410X.2012.10930.x","volume":"110","author":"M Roscigno","year":"2012","unstructured":"Roscigno M, Cha EK, Rink M, Seitz C, Novara G, Chromecki TF, et al. International validation of the prognostic value of subclassification for AJCC stage pT3 upper tract urothelial carcinoma of the renal pelvis. BJU Int. 2012;110:674\u201381.","journal-title":"BJU Int"},{"key":"9893_CR6","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1007\/s00428-020-02973-8","volume":"478","author":"T Sano","year":"2021","unstructured":"Sano T, Kato M, Sassa N, Sadachi R, Hirakawa A, Kamihira O, et al. pT3 subclassification of renal pelvic cancer considering the tumor location improves the patients\u2019 prognostic accuracy. Virchows Arch. 2021;478:1089\u201397.","journal-title":"Virchows Arch"},{"key":"9893_CR7","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s00428-020-02989-0","volume":"479","author":"K Kawamura","year":"2021","unstructured":"Kawamura K, Miyai K, Asakuma J, Sato K, Matsukuma S, Tsuda H, et al. Tumor budding in upper urinary tract urothelial carcinoma: a putative prognostic factor for extraurothelial recurrence and overall survival. Virchows Arch. 2021;479:45\u201355.","journal-title":"Virchows Arch"},{"key":"9893_CR8","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1016\/j.cell.2011.11.016","volume":"147","author":"P Friedl","year":"2011","unstructured":"Friedl P, Alexander S. Cancer invasion and the microenvironment: plasticity and reciprocity. Cell. 2011;147:992\u20131009.","journal-title":"Cell"},{"key":"9893_CR9","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/j.tips.2019.04.005","volume":"40","author":"X Zhuang","year":"2019","unstructured":"Zhuang X, Zhang H, Hu G. Cancer and microenvironment plasticity: double-edged swords in metastasis. Trends Pharmacol Sci. 2019;40:419\u201329.","journal-title":"Trends Pharmacol Sci"},{"key":"9893_CR10","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1359\/jbmr.1999.14.7.1239","volume":"14","author":"K Horiuchi","year":"1999","unstructured":"Horiuchi K, Amizuka N, Takeshita S, Takamatsu H, Katsuura M, Ozawa H, et al. Identification and characterization of a novel protein, periostin, with restricted expression to periosteum and periodontal ligament and increased expression by transforming growth factor beta. J Bone Miner Res. 1999;14:1239\u201349.","journal-title":"J Bone Miner Res"},{"key":"9893_CR11","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.canlet.2009.02.043","volume":"281","author":"Y Bai","year":"2009","unstructured":"Bai Y, Kakudo K, Nakamura M, Ozaki T, Li Y, Liu Z, et al. Loss of cellular polarity\/cohesiveness in the invasive front of papillary thyroid carcinoma and periostin expression. Cancer Lett. 2009;281:188\u201395.","journal-title":"Cancer Lett"},{"key":"9893_CR12","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/nature10694","volume":"481","author":"I Malanchi","year":"2011","unstructured":"Malanchi I, Santamaria-Mart\u00ednez A, Susanto E, Peng H, Lehr HA, Delaloye JF, et al. Interactions between cancer stem cells and their niche govern metastatic colonization. Nature. 2011;481:85\u20139.","journal-title":"Nature"},{"key":"9893_CR13","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1007\/s00018-009-0013-7","volume":"66","author":"K Ruan","year":"2009","unstructured":"Ruan K, Bao S, Ouyang G. The multifaceted role of periostin in tumorigenesis. Cell Mol Life Sci. 2009;66:2219\u201330.","journal-title":"Cell Mol Life Sci"},{"key":"9893_CR14","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1007\/s00428-011-1151-5","volume":"459","author":"L Morra","year":"2011","unstructured":"Morra L, Moch H. Periostin expression and epithelial-mesenchymal transition in cancer: a review and an update. Virchows Arch. 2011;459:465\u201375.","journal-title":"Virchows Arch"},{"key":"9893_CR15","doi-asserted-by":"publisher","first-page":"387","DOI":"10.2353\/ajpath.2010.090748","volume":"177","author":"J Soikkeli","year":"2010","unstructured":"Soikkeli J, Podlasz P, Yin M, Nummela P, Jahkola T, Virolainen S, et al. Metastatic outgrowth encompasses COL-I, FN1, and POSTN up-regulation and assembly to fibrillar networks regulating cell adhesion, migration, and growth. Am J Pathol. 2010;177:387\u2013403.","journal-title":"Am J Pathol"},{"key":"9893_CR16","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1038\/emboj.2011.469","volume":"31","author":"T Oskarsson","year":"2012","unstructured":"Oskarsson T, Massagu\u00e9 J. Extracellular matrix players in metastatic niches. EMBO J. 2012;31:254\u20136.","journal-title":"EMBO J"},{"key":"9893_CR17","doi-asserted-by":"publisher","first-page":"5072","DOI":"10.3390\/cancers13205072","volume":"13","author":"T Fujikawa","year":"2021","unstructured":"Fujikawa T, Sanada F, Taniyama Y, Shibata K, Katsuragi N, Koibuchi N, et al. Periostin exon-21 antibody neutralization of triple-negative breast cancer cell-derived periostin regulates tumor-associated macrophage polarization and angiogenesis. Cancers (Basel). 2021;13:5072.","journal-title":"Cancers (Basel)"},{"key":"9893_CR18","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.ejim.2016.11.015","volume":"38","author":"L Idolazzi","year":"2017","unstructured":"Idolazzi L, Ridolo E, Fassio A, Gatti D, Montagni M, Caminati M, et al. Periostin: the bone and beyond. Eur J Intern Med. 2017;38:12\u20136.","journal-title":"Eur J Intern Med"},{"key":"9893_CR19","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1002\/ijc.21120","volume":"117","author":"CJ Kim","year":"2005","unstructured":"Kim CJ, Yoshioka N, Tambe Y, Kushima R, Okada Y, Inoue H. Periostin is down-regulated in high grade human bladder cancers and suppresses in vitro cell invasiveness and in vivo metastasis of cancer cells. Int J Cancer. 2005;117:51\u20138.","journal-title":"Int J Cancer"},{"key":"9893_CR20","doi-asserted-by":"publisher","first-page":"23335","DOI":"10.18632\/oncotarget.8024","volume":"7","author":"CR Silvers","year":"2016","unstructured":"Silvers CR, Liu YR, Wu CH, Miyamoto H, Messing EM, Lee YF. Identification of extracellular vesicle-borne periostin as a feature of muscle-invasive bladder cancer. Oncotarget. 2016;7:23335\u201345.","journal-title":"Oncotarget"},{"key":"9893_CR21","first-page":"81","volume-title":"WHO Classification of Tumours of the Urinary System and Male Genital Organs","author":"DJ Grignon","year":"2016","unstructured":"Grignon DJ, Al-Ahmadie H, Algaba F, Amin MB, Comperat E, Dyrskjot L, et al. Infiltrating urothelial carcinoma. In: Moch H, Humphrey PA, Ulbright TM, Reuter VE, editors., et al., WHO Classification of Tumours of the Urinary System and Male Genital Organs. 4th ed. Lyon: IARC Press; 2016. p. 81\u201398.","edition":"4"},{"key":"9893_CR22","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1007\/978-3-319-40618-3_61","volume-title":"AJCC Cancer Staging Manual","author":"JM McKiernan","year":"2017","unstructured":"McKiernan JM, Hansel DE, Bochner BH, Efstathiou JA, Konety BR, Lee CT, et al. Renal pelvis and ureter. In: Amin MB, Edge S, Greene F, Byrd DR, Brookland RK, Washington MK, et al., editors. AJCC Cancer Staging Manual. 8th ed. New York: Springer International publishing; 2017. p. 757\u201363.","edition":"8"},{"key":"9893_CR23","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1038\/modpathol.2017.46","volume":"30","author":"A Lugli","year":"2017","unstructured":"Lugli A, Kirsch R, Ajioka Y, Bosman F, Cathomas G, Dawson H, et al. Recommendations for reporting tumor budding in colorectal cancer based on the International Tumor Budding Consensus Conference (ITBCC) 2016. Mod Pathol. 2017;30:1299\u2013311.","journal-title":"Mod Pathol"},{"key":"9893_CR24","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1111\/pin.13060","volume":"71","author":"J Ikeda","year":"2021","unstructured":"Ikeda J, Ohe C, Yoshida T, Kuroda N, Saito R, Kinoshita H, et al. Comprehensive pathological assessment of histological subtypes, molecular subtypes based on immunohistochemistry, and tumor-associated immune cell status in muscle-invasive bladder cancer. Pathol Int. 2021;71:173\u201382.","journal-title":"Pathol Int"},{"key":"9893_CR25","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1136\/jclinpath-2017-204562","volume":"71","author":"A Hodgson","year":"2018","unstructured":"Hodgson A, Xu B, Satkunasivam R, Downes MR. Tumour front inflammation and necrosis are independent prognostic predictors in high-grade urothelial carcinoma of the bladder. J Clin Pathol. 2018;71:154\u201360.","journal-title":"J Clin Pathol"},{"key":"9893_CR26","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1186\/1471-2407-10-273","volume":"10","author":"V Tischler","year":"2010","unstructured":"Tischler V, Fritzsche FR, Wild PJ, Stephan C, Seifert HH, Riener MO, et al. Periostin is up-regulated in high grade and high stage prostate cancer. BMC Cancer. 2010;10:273.","journal-title":"BMC Cancer"},{"key":"9893_CR27","doi-asserted-by":"publisher","first-page":"e1257","DOI":"10.1016\/j.clgc.2018.07.019","volume":"16","author":"C Cattrini","year":"2018","unstructured":"Cattrini C, Rubagotti A, Nuzzo PV, Zinoli L, Salvi S, Boccardo S, et al. Overexpression of periostin in tumor biopsy samples is associated with prostate cancer phenotype and clinical outcome. Clin Genitourin Cancer. 2018;16:e1257\u201365.","journal-title":"Clin Genitourin Cancer"},{"key":"9893_CR28","doi-asserted-by":"crossref","unstructured":"Lenfant L, Breda A, Xylinas E, Babjuk M, Moschini M, Roupr\u00eat M; EAU Section of Oncological Urology (ESOU) Board. Current Evidence and Future Perspectives in the Management of Nonmetastatic Upper Tract Urothelial Carcinoma. Eur Urol Oncol. 2021;S2588-9311(21):00154-1. [online ahead of print].","DOI":"10.1016\/j.euo.2021.09.002"},{"key":"9893_CR29","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.clgc.2014.02.005","volume":"12","author":"PV Nuzzo","year":"2014","unstructured":"Nuzzo PV, Buzzatti G, Ricci F, Rubagotti A, Argellati F, Zinoli L, et al. Periostin: a novel prognostic and therapeutic target for genitourinary cancer? Clin Genitourin Cancer. 2014;12:301\u201311.","journal-title":"Clin Genitourin Cancer"},{"key":"9893_CR30","first-page":"1759","volume":"38","author":"CJ Kim","year":"2011","unstructured":"Kim CJ, Sakamoto K, Tambe Y, Inoue H. Opposite regulation of epithelial-to-mesenchymal transition and cell invasiveness by periostin between prostate and bladder cancer cells. Int J Oncol. 2011;38:1759\u201366.","journal-title":"Int J Oncol"},{"key":"9893_CR31","first-page":"161","volume":"32","author":"CJ Kim","year":"2008","unstructured":"Kim CJ, Isono T, Tambe Y, Chano T, Okabe H, Okada Y, et al. Role of alternative splicing of periostin in human bladder carcinogenesis. Int J Oncol. 2008;32:161\u20139.","journal-title":"Int J Oncol"},{"key":"9893_CR32","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/j.clgc.2013.05.001","volume":"11","author":"W Otto","year":"2013","unstructured":"Otto W, Denzinger S, Fritsche HM, Burger M, R\u00f6\u00dfler W, Bertz S, et al. Introduction and first clinical application of a simplified immunohistochemical validation system confirms prognostic impact of KI-67 and CK20 for stage T1 urothelial bladder carcinoma: single-center analysis of eight biomarkers in a series of three hundred six patients. Clin Genitourin Cancer. 2013;11:537\u201344.","journal-title":"Clin Genitourin Cancer"},{"key":"9893_CR33","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.euo.2020.12.007","volume":"4","author":"JP Sfakianos","year":"2021","unstructured":"Sfakianos JP, Gul Z, Shariat SF, Matin SF, Daneshmand S, Plimack E, et al. Genetic differences between bladder and upper urinary tract carcinoma: implications for therapy. Eur Urol Oncol. 2021;4:170\u20139.","journal-title":"Eur Urol Oncol"},{"key":"9893_CR34","doi-asserted-by":"publisher","first-page":"2977","DOI":"10.1038\/s41467-019-10873-y","volume":"10","author":"BD Robinson","year":"2019","unstructured":"Robinson BD, Vlachostergios PJ, Bhinder B, Liu W, Li K, Moss TJ, et al. Upper tract urothelial carcinoma has a luminal-papillary T-cell depleted contexture and activated FGFR3 signaling. Nat Commun. 2019;10:2977.","journal-title":"Nat Commun"},{"key":"9893_CR35","doi-asserted-by":"publisher","first-page":"306","DOI":"10.4132\/jptm.2017.01.19","volume":"51","author":"HJ Oh","year":"2017","unstructured":"Oh HJ, Bae JM, Wen XY, Cho NY, Kim JH, Kang GH. Overexpression of POSTN in tumor stroma is a poor prognostic indicator of colorectal cancer. J Pathol Transl Med. 2017;51:306\u201313.","journal-title":"J Pathol Transl Med"},{"key":"9893_CR36","doi-asserted-by":"publisher","first-page":"445","DOI":"10.3892\/ol.2021.12706","volume":"21","author":"N Yamauchi","year":"2021","unstructured":"Yamauchi N, Kanke Y, Saito K, Okayama H, Yamada S, Nakajima S, et al. Stromal expression of cancer-associated fibroblast-related molecules, versican and lumican, is strongly associated with worse relapse-free and overall survival times in patients with esophageal squamous cell carcinoma. Oncol Lett. 2021;21:445.","journal-title":"Oncol Lett"},{"key":"9893_CR37","doi-asserted-by":"publisher","first-page":"225","DOI":"10.3389\/fonc.2018.00225","volume":"8","author":"L Gonz\u00e1lez-Gonz\u00e1lez","year":"2018","unstructured":"Gonz\u00e1lez-Gonz\u00e1lez L, Alonso J. Periostin: a matricellular protein with multiple functions in cancer development and progression. Front Oncol. 2018;8:225.","journal-title":"Front Oncol"},{"key":"9893_CR38","doi-asserted-by":"publisher","first-page":"6871s","DOI":"10.1158\/1078-0432.CCR-07-1151","volume":"13","author":"RR Turner","year":"2007","unstructured":"Turner RR, Li C, Compton CC. Newer pathologic assessment techniques for colorectal carcinoma. Clin Cancer Res. 2007;13:6871s-s6876.","journal-title":"Clin Cancer Res"},{"key":"9893_CR39","doi-asserted-by":"publisher","first-page":"3659","DOI":"10.1111\/all.15089","volume":"76","author":"I Ogulur","year":"2021","unstructured":"Ogulur I, Pat Y, Ardicli O, Barletta E, Cevhertas L, Fernandez-Santamaria R, et al. Advances and highlights in biomarkers of allergic diseases. Allergy. 2021;76:3659\u201386.","journal-title":"Allergy"},{"key":"9893_CR40","doi-asserted-by":"publisher","first-page":"169","DOI":"10.3390\/ijms20010169","volume":"20","author":"F Ohno","year":"2019","unstructured":"Ohno F, Nakahara T, Kido-Nakahara M, Ito T, Nunomura S, Izuhara K, et al. Periostin Links Skin Inflammation to Melanoma Progression in Humans and Mice. Int J Mol Sci. 2019;20:169.","journal-title":"Int J Mol Sci"},{"key":"9893_CR41","doi-asserted-by":"publisher","first-page":"7725","DOI":"10.2147\/OTT.S222422","volume":"12","author":"LA Wang","year":"2019","unstructured":"Wang LA, Yang B, Rao W, Xiao H, Wang D, Jiang J. The correlation of BER protein, IRF3 with CD8+ T cell and their prognostic significance in upper tract urothelial carcinoma. Onco Targets Ther. 2019;12:7725\u201335.","journal-title":"Onco Targets Ther"},{"key":"9893_CR42","doi-asserted-by":"publisher","first-page":"1861737","DOI":"10.1080\/2162402X.2020.1861737","volume":"10","author":"S Cheng","year":"2021","unstructured":"Cheng S, Zhong W, Xia K, Hong P, Lin R, Wang B, et al. Prognostic role of stromal tumor-infiltrating lymphocytes in locally advanced upper tract urothelial carcinoma: A retrospective multicenter study (TSU-02 study). Oncoimmunology. 2021;10:1861737.","journal-title":"Oncoimmunology"},{"key":"9893_CR43","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1007\/s00262-020-02499-7","volume":"69","author":"A Nukui","year":"2020","unstructured":"Nukui A, Kamai T, Arai K, Kijima T, Kobayashi M, Narimatsu T, et al. Association of cancer progression with elevated expression of programmed cell death protein 1 ligand 1 by upper tract urothelial carcinoma and increased tumor-infiltrating lymphocyte density. Cancer Immunol Immunother. 2020;69:689\u2013702.","journal-title":"Cancer Immunol Immunother"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-022-09893-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-022-09893-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-022-09893-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,18]],"date-time":"2022-07-18T06:18:39Z","timestamp":1658125119000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-022-09893-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,18]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["9893"],"URL":"https:\/\/doi.org\/10.1186\/s12885-022-09893-7","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,18]]},"assertion":[{"value":"27 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 July 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed in accordance with the Declaration of Helsinki and approved by the Ethics Committee of the National Defense Medical College (registration number: 4007). All patients agreed to participate in this study, and written informed consent was obtained from all patients.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"787"}}